235 related articles for article (PubMed ID: 33873075)
1. Fast-acting insulin aspart (Fiasp®) improves glycemic outcomes when used with MiniMed
Grosman B; Wu D; Parikh N; Roy A; Voskanyan G; Kurtz N; Sturis J; Cohen O; Ekelund M; Vigersky R
Comput Methods Programs Biomed; 2021 Jun; 205():106087. PubMed ID: 33873075
[TBL] [Abstract][Full Text] [Related]
2. Fast-Acting Insulin Aspart Use with the MiniMed
Hsu L; Buckingham B; Basina M; Ekhlaspour L; von Eyben R; Wang J; Lal RA
Diabetes Technol Ther; 2021 Jan; 23(1):1-7. PubMed ID: 32520594
[No Abstract] [Full Text] [Related]
3. Fast Acting Insulin Aspart Compared with Insulin Aspart in the Medtronic 670G Hybrid Closed Loop System in Type 1 Diabetes: An Open Label Crossover Study.
Ozer K; Cooper AM; Ahn LP; Waggonner CR; Blevins TC
Diabetes Technol Ther; 2021 Apr; 23(4):286-292. PubMed ID: 33090016
[TBL] [Abstract][Full Text] [Related]
4. Safety, metabolic and psychological outcomes of Medtronic MiniMed 670G in children, adolescents and young adults: a systematic review.
Mameli C; Smylie GM; Galati A; Rapone B; Cardona-Hernandez R; Zuccotti G; Delvecchio M
Eur J Pediatr; 2023 May; 182(5):1949-1963. PubMed ID: 36809498
[TBL] [Abstract][Full Text] [Related]
5. Retrospective Analysis of 3-Month Real-World Glucose Data After the MiniMed 670G System Commercial Launch.
Stone MP; Agrawal P; Chen X; Liu M; Shin J; Cordero TL; Kaufman FR
Diabetes Technol Ther; 2018 Oct; 20(10):689-692. PubMed ID: 30160523
[TBL] [Abstract][Full Text] [Related]
6. Cost-Effectiveness Analysis of the MiniMed 670G Hybrid Closed-Loop System Versus Continuous Subcutaneous Insulin Infusion for Treatment of Type 1 Diabetes.
Jendle J; Pöhlmann J; de Portu S; Smith-Palmer J; Roze S
Diabetes Technol Ther; 2019 Mar; 21(3):110-118. PubMed ID: 30785311
[TBL] [Abstract][Full Text] [Related]
7. Hybrid closed-loop glucose control with faster insulin aspart compared with standard insulin aspart in adults with type 1 diabetes: A double-blind, multicentre, multinational, randomized, crossover study.
Boughton CK; Hartnell S; Thabit H; Poettler T; Herzig D; Wilinska ME; Ashcroft NL; Sibayan J; Cohen N; Calhoun P; Bally L; Mader JK; Evans M; Leelarathna L; Hovorka R
Diabetes Obes Metab; 2021 Jun; 23(6):1389-1396. PubMed ID: 33606901
[TBL] [Abstract][Full Text] [Related]
8. A Comparison of Postprandial Glucose Control in the Medtronic Advanced Hybrid Closed-Loop System Versus 670G.
Weinzimer SA; Bailey RJ; Bergenstal RM; Nimri R; Beck RW; Schatz D; Ambler-Osborn L; Schweiger DS; von dem Berge T; Sibayan J; Johnson ML; Calhoun P; Phillip M;
Diabetes Technol Ther; 2022 Aug; 24(8):573-582. PubMed ID: 35363054
[No Abstract] [Full Text] [Related]
9. Maximizing Glycemic Benefits of Using Faster Insulin Formulations in Type 1 Diabetes: In Silico Analysis Under Open- and Closed-Loop Conditions.
Diaz C JL; Colmegna P; Breton MD
Diabetes Technol Ther; 2023 Apr; 25(4):219-230. PubMed ID: 36595379
[No Abstract] [Full Text] [Related]
10. A fully artificial pancreas versus a hybrid artificial pancreas for type 1 diabetes: a single-centre, open-label, randomised controlled, crossover, non-inferiority trial.
Tsoukas MA; Majdpour D; Yale JF; Fathi AE; Garfield N; Rutkowski J; Rene J; Legault L; Haidar A
Lancet Digit Health; 2021 Nov; 3(11):e723-e732. PubMed ID: 34580055
[TBL] [Abstract][Full Text] [Related]
11. Switching from Suspend-Before-Low Insulin Pump Technology to a Hybrid Closed-Loop System Improves Glucose Control and Reduces Glucose Variability: A Retrospective Observational Case-Control Study.
Lepore G; Scaranna C; Corsi A; Dodesini AR; Trevisan R
Diabetes Technol Ther; 2020 Apr; 22(4):321-325. PubMed ID: 31617752
[TBL] [Abstract][Full Text] [Related]
12. Comparable Glucose Control with Fast-Acting Insulin Aspart Versus Insulin Aspart Using a Second-Generation Hybrid Closed-Loop System During Exercise.
Morrison D; Zaharieva DP; Lee MH; Paldus B; Vogrin S; Grosman B; Roy A; Kurtz N; O'Neal DN
Diabetes Technol Ther; 2022 Feb; 24(2):93-101. PubMed ID: 34524022
[No Abstract] [Full Text] [Related]
13. Safety Evaluation of the MiniMed 670G System in Children 7-13 Years of Age with Type 1 Diabetes.
Forlenza GP; Pinhas-Hamiel O; Liljenquist DR; Shulman DI; Bailey TS; Bode BW; Wood MA; Buckingham BA; Kaiserman KB; Shin J; Huang S; Lee SW; Kaufman FR
Diabetes Technol Ther; 2019 Jan; 21(1):11-19. PubMed ID: 30585770
[TBL] [Abstract][Full Text] [Related]
14. In-Clinic Evaluation of the MiniMed 670G System "Suspend Before Low" Feature in Children with Type 1 Diabetes.
Wood MA; Shulman DI; Forlenza GP; Bode BW; Pinhas-Hamiel O; Buckingham BA; Kaiserman KB; Liljenquist DR; Bailey TS; Shin J; Huang S; Chen X; Cordero TL; Lee SW; Kaufman FR
Diabetes Technol Ther; 2018 Nov; 20(11):731-737. PubMed ID: 30299976
[TBL] [Abstract][Full Text] [Related]
15. A comparison of two hybrid closed-loop systems in adolescents and young adults with type 1 diabetes (FLAIR): a multicentre, randomised, crossover trial.
Bergenstal RM; Nimri R; Beck RW; Criego A; Laffel L; Schatz D; Battelino T; Danne T; Weinzimer SA; Sibayan J; Johnson ML; Bailey RJ; Calhoun P; Carlson A; Isganaitis E; Bello R; Albanese-O'Neill A; Dovc K; Biester T; Weyman K; Hood K; Phillip M;
Lancet; 2021 Jan; 397(10270):208-219. PubMed ID: 33453783
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Real-Life Usage of MiniMed 670G Automode in Children with Type 1 Diabetes Less than 7 Years Old.
Salehi P; Roberts AJ; Kim GJ
Diabetes Technol Ther; 2019 Aug; 21(8):448-451. PubMed ID: 31166801
[TBL] [Abstract][Full Text] [Related]
17. Glycemic outcomes of children 2-6 years of age with type 1 diabetes during the pediatric MiniMed™ 670G system trial.
Forlenza GP; Ekhlaspour L; DiMeglio LA; Fox LA; Rodriguez H; Shulman DI; Kaiserman KB; Liljenquist DR; Shin J; Lee SW; Buckingham BA
Pediatr Diabetes; 2022 May; 23(3):324-329. PubMed ID: 35001477
[TBL] [Abstract][Full Text] [Related]
18. Cost-Effectiveness of Hybrid Closed Loop Insulin Pumps Versus Multiple Daily Injections Plus Intermittently Scanned Glucose Monitoring in People With Type 1 Diabetes in The Netherlands.
Serné EH; Roze S; Buompensiere MI; Valentine WJ; De Portu S; de Valk HW
Adv Ther; 2022 Apr; 39(4):1844-1856. PubMed ID: 35226346
[TBL] [Abstract][Full Text] [Related]
19. An analysis of Medtronic MiniMed 670G insulin pump use in clinical practice and the impact on glycemic control, quality of life, and compliance.
Horowitz ME; Kaye WA; Pepper GM; Reynolds KE; Patel SR; Knudson KC; Kale GK; Gutierrez ME; Cotto LA; Horowitz BS
Diabetes Res Clin Pract; 2021 Jul; 177():108876. PubMed ID: 34058303
[TBL] [Abstract][Full Text] [Related]
20. Prospective Analysis of the Impact of Commercialized Hybrid Closed-Loop System on Glycemic Control, Glycemic Variability, and Patient-Related Outcomes in Children and Adults: A Focus on Superiority Over Predictive Low-Glucose Suspend Technology.
Beato-Víbora PI; Gallego-Gamero F; Lázaro-Martín L; Romero-Pérez MDM; Arroyo-Díez FJ
Diabetes Technol Ther; 2020 Dec; 22(12):912-919. PubMed ID: 31855446
[No Abstract] [Full Text] [Related]
[Next] [New Search]
